MDV3100 for castration resistant cancer

[Guest guest]

There's an article in Oncology Stat about the new drug MDV3100.  See:

http://www.oncologystat.com/viewpoints/commentary/MDV3100_Extends_Survival_in_Me\

n_With_Late_Stage_Prostate_Cancer_The_AFFIRM_Trial.html

To see it you'll need to register, but registration is free.

The author thinks that the MDV3100 and Abiraterone trials show that many men who

have been declared hormone refractory may not yet be hormone refractory.  He

calls such men " castration resistant " rather than " hormone refractory " .

If I understand him correctly, he also thinks that these new drugs can have a

greater impact if given earlier than they were given in the trials, and he

thinks that it makes sense to combine MDV3100 or Abiraterone with Alpharadin,

the drug that carries radioactive particles to bone lesions.  The hormone

manipulation drugs and Alpharadin have different principles of action and

different side effect profiles that, he thinks, are complementary to each other.

 

--

Alan Meyer

ameyer2@...